2016
Prognostic Significance of Surfactant Protein A, Surfactant Protein D, Clara Cell Protein 16, S100 Protein, Trefoil Factor 3, and Prostatic Secretory Protein 94 in Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Chronic Pulmonary Obstructive Disease
DOUBKOVÁ, Martina, Michal KARPISEK, Jiri MAZOCH, Jana SKŘIČKOVÁ, Michael DOUBEK et. al.Basic information
Original name
Prognostic Significance of Surfactant Protein A, Surfactant Protein D, Clara Cell Protein 16, S100 Protein, Trefoil Factor 3, and Prostatic Secretory Protein 94 in Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Chronic Pulmonary Obstructive Disease
Authors
DOUBKOVÁ, Martina (203 Czech Republic, belonging to the institution), Michal KARPISEK (203 Czech Republic), Jiri MAZOCH (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Michael DOUBEK (203 Czech Republic, belonging to the institution)
Edition
Sarcoidosis Vasculitis and Diffuse Lung Diseases, Fidenza, Mattioli 1885, 2016, 1124-0490
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
30203 Respiratory systems
Country of publisher
Italy
Confidentiality degree
is not subject to a state or trade secret
Impact factor
Impact factor: 1.575
RIV identification code
RIV/00216224:14110/16:00092064
Organization unit
Faculty of Medicine
UT WoS
000393274000005
Keywords in English
surfactant protein A; surfactant protein D; Clara cell protein 16; SIOO protein; trefoil factor 3
Tags
International impact, Reviewed
Changed: 22/3/2017 11:54, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
Background: Identification of serum and bronchoalveolar lavage fluid (BALF) biomarkers may facilitate diagnosis and prognostication in various lung disorders. Objective: Serum and BALF levels of surfactant protein A (SP-A), surfactant protein D (SP-D), Clara cell protein 16 (CC16), SIOO protein, trefoil factor 3 (TFF3), and prostatic secretory protein 94 (PSP94) were evaluated in 94 consecutive patients (idiopathic pulmonary fibrosis (IFF; n=18), sarcoidosis (n=25), chronic obstructive pulmonary disease (COPD; n=51)), and in 155 healthy controls. Methods: Biomarkers were measured at diagnosis and compared with disease characteristics. Both uniparametric and multiparametric analyses were used. Results: Seven significant correlations were found: 1) BALF PSP94 level correlated with prognosis of sarcoidosis (P=0.035); 2) BALF SP-D level with pulmonary functions in IFF (P=0.032); 3) BALF SP-D and TFF3 with IFF mortality (P=0.049 and 0.017, respectively); 4) serum TFF3 level with COPD mortality (P=0.006,); 5) serum SP-A with pulmonary functions impairment in IFF (P=0.011); 6) serum SP-D level was associated with HRCT interstitial score in IPF (P=0.0346); and 7) serum SP-A was associated with staging of COPD according to spirometry (P<0.001). Moreover, our analysis showed that some biomarker levels differed significantly among the diseases: 1) BALF SP-D level differed between sarcoidosis and IPF; 2) serum SP-A level differed among IPF, sarcoidosis, COPD and was also different from healthy controls; 3) serum S100A6, S100A11 levels differed among IPF, sarcoidosis, COPD from healthy controls 4) serum SP-D, CC16, TFF-3 levels distinguished IPF patients from healthy controls; and 5) serum CC16, TFF3, PSP94 distinguished COPD patients from healthy controls. Our study shows that some of selected biomarkers should have prognostic value in the analysed lung disorders. On the other hand, these biomarkers do not appear to be unequivocally suitable for differential diagnosis of these disorders.